This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In an interview, Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, professor of practice, sciences, and health outcomes research at the University of Maryland, explored the evolving landscape of vaccine recommendations, emphasizing the critical role pharmacists play in guiding patients through complex medical information.
Panelists discuss how pharmacists should educate patients about pneumococcal vaccines by providing current vaccine information statements (VIS) updated May 29, 2025, explaining common adverse effects like injection site reactions and mild systemic symptoms as normal immune responses, conducting thorough pre-vaccination screening for moderate-to-severe (..)
Kevin Cleveland, PharmD, discusses how pharmacists are uniquely positioned to provide immediate, direct interactions with patients, making them vital in addressing vaccine misinformation.
In an interview on vaccine recommendations, health care professionals expressed growing concerns about the changing landscape of medical information dissemination. Health care professionals emphasize patient education and reliable information in the evolving vaccine recommendation landscape.
In 2022, the Advisory Committee on Immunization Practices (ACIP) published updated pneumococcal vaccine recommendations. In 2022, the Advisory Committee on Immunization Practices (ACIP) published updated pneumococcal vaccine recommendations. Of those, 38% had evidence of pneumococcal vaccination prior to January 2022.
Garofoli, PharmD, BCACP, CTTS, FAPhA Publication Article Drug Topics Journal Drug Topics May/June 2025 Volume 169 Issue 03 Pharmacy team members can help patients prepare for upcoming travels, ensuring they are up to date with the recommended vaccines for their locations. The first resource is the CDC’s Yellow Book.
Panelists discuss how pharmacists should ensure patients receive at least one conjugated pneumococcal vaccine (PCV-15, PCV-20, or PCV-21) as the foundation of protection, with subsequent vaccine sequencing depending on which initial vaccine was given—where PCV-15 recipients should receive PPSV-23 one year later for additional serotype coverage, patients (..)
Experts discuss the recent dismissal of all 17 members of the Advisory Committee on Immunization Practices (ACIP), a panel that provides guidance to the CDC on vaccine recommendations. This abrupt change has raised significant concerns within the health care community about the potential impact on vaccine trust and public health policy.
Panelists discuss how pneumococcal vaccines differ between conjugated vaccines (PCV-15, PCV-20, PCV-21) and polysaccharide vaccines (PPSV-23) in terms of immune response mechanisms and serotype coverage, with current CDC recommendations now including all adults aged 50 and older for vaccination while maintaining risk-based recommendations for adults (..)
Panelists discuss how patients who previously completed pneumococcal vaccination with both PCV-13 and PPSV-23 may benefit from additional conjugate vaccine coverage with PCV-20 or PCV-21, with specific timing recommendations based on age and risk factors—including waiting at least 5 years after the last dose for high-risk patients under 50, following (..)
Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, highlights the critical role pharmacists play in navigating vaccine recommendations and supporting patient understanding.
Deanna Tran, PharmD, BCACP, FAPhA, emphasizes community outreach, especially in areas with high vaccine hesitancy, as a crucial strategy for maintaining public trust in vaccination programs.
As concerns mount over potential shifts in vaccine recommendations, Deanna Tran, PharmD, BCACP, FAPhA, advocates for rigorous data assessment and patient-centered communication strategies.
Panelists discuss how ACIP's decision to lower the pneumococcal conjugate vaccine age recommendation from 65 to 50 years was supported by evidence showing that 33-54% of adults aged 50-64 already had risk factors for vaccination, nearly 90% of those hospitalized with pneumococcal disease in this age group had at least one risk condition, mortality (..)
Lauren Angelo, PharmD, MBA, associate dean of academic affairs at Rosalind Franklin University of Medicine and Science, highlights significant concerns about the evolving landscape of COVID-19 vaccine policy.
Researchers wanted to address the potential impact of pharmacist-led influenza immunization services on vaccine uptake in older adults living in Denmark.
Researchers conducted a systematic review and meta-analysis to estimate vaccine coverage and identify factors associated with vaccination among forcibly displaced, pediatric populations.
The shift away from thimerosal may increase the use of single-dose syringes, impacting vaccination practices in various healthcare settings. ACIP's recommendations are increasingly significant for pharmacies, influencing vaccination planning, billing, and patient care activities.
Today, we’re speaking to Simone Steiner, Transgene’s new chief technology officer, about how the company is transitioning from early- to late-stage testing and advancing its manufacturing capabilities Oncology vaccines are gaining traction in the clinic as potential game changing treatments for cancer.
A federal vaccine advisory panel, which health secretary Robert F. recently stacked with handpicked members , recommended on Thursday that Americans should not receive flu vaccines containing the preservative thimerosal. Kennedy Jr.
to remove and replace all members of the government’s independent vaccine advisory committee doesn’t just change how the nation will approach vaccine policy. Kennedy Jr. It could also take money out of Americans’ wallets. Continue to STAT+ to read the full story…
WASHINGTON — A key Senate health leader is calling for this week’s meeting of the panel of vaccine advisers handpicked by Health and Human Services Secretary Robert F. to be delayed, citing their lack of experience and potential bias against some vaccines. Kennedy Jr. Bill Cassidy (R-La.) Read the rest…
Childhood vaccination coverage has made leaps since 1980. That is according to a study published in The Lancet Tuesday, which found stagnation and wide variation in childhood vaccination rates since 2010. But progress has significantly slowed in the last two decades.
An expert discusses how pharmacists can overcome common vaccination barriers by addressing misconceptions about vaccine necessity, making strong provider recommendations, and educating patients about mild adverse effects while building trust through consistent communication.
Panelists discuss that building trust with vaccine-hesitant patients requires pharmacists to slow down, listen empathetically, and ask open-ended questions to understand individual concerns; by addressing specific fears with clear, tailored information and practicing cultural sensitivity, pharmacists can foster ongoing, respectful dialogue that gradually (..)
An expert discusses how pharmacists should follow CDC immunization schedules for different age groups and use shared clinical decision-making for patients with prior vaccination history, while considering contraindications primarily related to severe allergic reactions to vaccine components.
Panelists discuss the 3 FDA-approved RSV vaccines for high-risk adults—2 recombinant protein-based (1 adjuvanted, 1 bivalent) and one mRNA-based—highlighting differences in formulation, mechanism, and preparation, and emphasizing the importance of education to address misconceptions and guide appropriate vaccine selection.
Panelists discuss recent safety updates on RSV vaccines, including a rare potential risk of Guillain-Barré syndrome (GBS) in older adults receiving recombinant vaccines, emphasizing that benefits outweigh risks and highlighting the pharmacist’s role in educating patients about common adverse effects, recognizing early signs of rare adverse events, (..)
With the Advisory Committee on Immunization Practices recommending that adults receive thimerosal-free influenza vaccines, the preservative that was phased out of most childhood vaccines in 2001 has reentered the public eye.
In a community of older adults, initiating a pneumococcal vaccination support program reduced annual pneumonia-related mortality by 25%, demonstrating broad public and individual health benefits.
Panelists discuss how community pharmacies have become trusted hubs for adult vaccinations, with pharmacists not only administering vaccines but also educating patients and coordinating with other health care providers to ensure clear, unified messaging; they emphasize the importance of collaboration, empowering pharmacists to use clinical judgment, (..)
Panelists discuss how pharmacists can address patients’ growing vaccine fatigue and misconceptions—such as underestimating RSV’s severity in adults or believing it requires multiple doses—by providing clear, consistent education and emphasizing that a single RSV vaccine offers protection against serious illness in high-risk populations.
New research reveals that extracellular vesicles enhance intranasal flu vaccines, boosting mucosal immunity and offering broader protection against diverse strains.
Six years following vaccination with 23-valent pneumococcal polysaccharide vaccine in a Chinese population, antibody levels remained high, though not as high as 28 days following vaccination.
Panelists discuss vaccine hesitancy surrounding the new RSV vaccine, highlighting factors such as uncertainty about safety and effectiveness, cost concerns, limited health literacy, language barriers, and lingering skepticism fueled by the COVID-19 pandemic, emphasizing how pharmacists can address these issues through tailored education, insurance (..)
An expert discusses how pharmacists can evaluate patients with prior adverse vaccine reactions by distinguishing between mild local reactions and serious anaphylactic responses, then recommending supervised vaccination or medical center administration when appropriate.
Expanding use of the 15-valent pneumococcal conjugate vaccine (PCV15) or 20-valent pneumococcal conjugate vaccine (PCV20) to all United States adults aged 50 to 64 years would result in modest budget increases over a 3-year period. 1,2 A particular disease burden is present for Black Americans.
Adam James, PharmD, and Chris Altman, PharmD, discuss renewed public scrutiny of thimerosal, its limited use in vaccines today, and how new guidance may affect pharmacists and patient confidence moving forward.
Panelists discuss that pharmacies should prioritize practical workflow and patient management over clinical preference when administering RSV vaccines, since all FDA-approved vaccines are equally recommended; focusing on factors like preparation ease, storage, patient eligibility, and insurance helps streamline operations and promote timely vaccination (..)
French biopharma, Osivax, has announced positive results from its phase 2 study, OVX836-004, into OVX836, its broad-spectrum influenza vaccine lead candidate. The results have been published in the journal, Vaccines.
An expert discusses how the 5 FDA-approved pneumococcal vaccines differ, with newer conjugate vaccines like PCV20 and PCV21 offering broader serotype coverage and better immune memory compared with the older polysaccharide vaccine, though geographic factors may influence vaccine selection.
Panelists discuss strategies to address patient hesitancy around receiving multiple vaccines—flu, COVID-19, and RSV—simultaneously during the fall, emphasizing CDC recommendations for co-administration, educating patients about manageable adverse effects, tailoring conversations to individual concerns, and encouraging year-round RSV vaccination to (..)
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content